Shots:
- Simcere Zaiming has entered into an exclusive global licensing agreement with Roche for the development & commercialization of SIM0660, a potential treatment of B-cell-mediated diseases
- As per the deal, Roche will acquire exclusive global rights to develop, manufacture, & commercialize SIM0660 in exchange for ~$1.53B in total, incl. $75M in upfront, as well as Simcere will receive tiered royalties of up to double digits on future net sales
- SIM0660 is a tri-specific antibody developed using T-cell engager poly-specific antibody technology that combines CD3 engagement with CD79a and CD19 targeting to drive potent T-cell-mediated cytotoxicity while limiting cytokine release
Ref: PRnewswire | Image: Simcere & Roche | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
